The ASCO Post

Addition of Palbociclib to Standard Therapy in Metastatic Hormone Receptor–Positive, HER2-Positive Breast Cancer

Addition of the CDK4/6 inhibitor palbociclib to the current standard of care for first-line maintenance therapy after induction chemotherapy achieved statistically significant and clinically meaningful improvements in progression-free survival in patients with HR-positive, HER2-positive metastatic breast cancer.

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) in 1996, covering eight tumor types. Today, guidelines are available for more than 60 tumor types, subtypes, and related topics. During the NCCN’s 30th Annual Conference, updates to the guidelines were presented for several of those malignancies.

OlympiA Trial: Long-Term Benefits of Olaparib Confirmed in High-Risk Subgroup of Breast Cancer

For women with high-risk, BRCA-positive breast cancer, 1 year of adjuvant treatment with the PARP inhibitor olaparib following primary treatment continued to improve overall survival compared with placebo, according to 6-year follow-up of the phase III OlympiA trial.

Is There a Link Between Tattoos and Increased Cancer Risk?

Investigators examined the risk of skin cancers and lymphoma among individuals with tattoos compared with those without tattoos.

Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL

Can the addition of polatuzumab vedotin-piiq to rituximab, gemcitabine, and oxaliplatin improve survival outcomes for some patients with DLBCL? The phase III trial POLARGO investigators share their results.

Thermal Ablation vs Surgical Resection of Small Resectable Colorectal Liver Metastases

A phase III noninferiority trial compared survival outcomes with thermal ablation vs surgical resection in patients who had small, resectable, colorectal liver metastases.

HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings

Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials.

Revisiting Margin Width Guidelines for Ductal Carcinoma In Situ and the Role of Routine Reexcision

For postmenopausal women with HR-positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider surgical margins may not be necessary.

Final Overall Survival Analysis of FLAURA2: Osimertinib Plus Chemotherapy in EGFR-Mutant NSCLC

The final overall survival analysis demonstrates consistent survival benefit, as previously reported in the interim overall survival results, and builds on the previously presented primary endpoint data, which demonstrated the longest-reported median progression-free survival in this setting with the regimen.

Adjuvant Dose-Dense vs Conventional Chemotherapy in Node-Positive Breast Cancer

Long-term clinical trial follow-up showed how adjuvant dose-dense chemotherapy compared with conventional chemotherapy in patients with node-positive breast cancer.